Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Crinetics Pharmaceuticals (Nasdaq: CRNX) will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.
Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update. Dial-in numbers are provided for domestic and international callers and the access code 166837 applies. A live webcast will be available via the company's Events/Investor Relations pages and will be archived for later viewing. Participants are recommended to connect at least 15 minutes before the scheduled start to ensure a timely connection.
Crinetics Pharmaceuticals (Nasdaq: CRNX) riporterà i risultati finanziari del terzo trimestre 2025 il giovedì 6 novembre 2025 dopo la chiusura del mercato.
La direzione terrà una conference call e una webcast alle 16:30 ET per discutere i risultati e fornire un aggiornamento sull'andamento aziendale. I numeri di accesso sono forniti per chiamanti nazionali e internazionali e vale il codice di accesso 166837. Una webcast in diretta sarà disponibile tramite le pagine Events/Investor Relations dell'azienda e sarà archiviata per una visione successiva. Si raccomanda ai partecipanti di collegarsi almeno 15 minuti prima dell'orario di inizio previsto per garantire una connessione tempestiva.
Crinetics Pharmaceuticals (Nasdaq: CRNX) informará los resultados financieros del tercer trimestre de 2025 el jueves 6 de noviembre de 2025 después del cierre del mercado.
La dirección organizará una llamada de conferencia y una transmisión en vivo a las 4:30 p.m. ET para discutir los resultados y proporcionar una actualización de negocio. Se proporcionan números de marcación para llamadas nacionales e internacionales y se aplica el código de acceso 166837. Una transmisión en vivo estará disponible a través de las páginas de Eventos/Relaciones con Inversores de la empresa y quedará archivada para su visualización posterior. Se recomienda a los participantes conectarse al menos 15 minutos antes del inicio programado para garantizar una conexión oportuna.
Crinetics Pharmaceuticals (Nasdaq: CRNX)은 2025년 3사분기 실적을 2025년 11월 6일 목요일 장 마감 이후에 발표합니다.
경영진은 동부표준시 기준 오후 4시 30분에 컨퍼런스 콜 및 웹캐스트를 주최하여 결과를 논의하고 비즈니스 업데이트를 제공합니다. 국내외 호출자를 위한 다이얼 인 번호가 제공되며 접속 코드 166837가 적용됩니다. 회사의 이벤트/투자자 관계 페이지를 통해 라이브 웹캐스트를 이용할 수 있으며 나중에 보기 위해 보관됩니다. 원활한 연결을 보장하기 위해 예정 시작 시각 최소 15분 전에 접속하는 것이 권장됩니다.
Crinetics Pharmaceuticals (Nasdaq: CRNX) publiera les résultats financiers du troisième trimestre 2025 après la clôture du marché, le jeudi 6 novembre 2025.
La direction animera une conférence téléphonique et une diffusion en direct à 16h30 HNE pour discuter des résultats et fournir une mise à jour de l'activité. Des numéros d'appel sont fournis pour les appelants nationaux et internationaux et le code d'accès 166837 s'applique. Une diffusion en direct sera disponible via les pages Événements/Relations investisseurs de l'entreprise et sera archivée pour une visualisation ultérieure. Il est recommandé aux participants de se connecter au moins 15 minutes avant l'heure de début prévue pour assurer une connexion en temps utile.
Crinetics Pharmaceuticals (Nasdaq: CRNX) wird die Finanzergebnisse für das dritte Quartal 2025 nach Börsenschluss am Donnerstag, 6. November 2025 bekannt geben.
Das Management wird eine Telefonkonferenz und Webcast um 16:30 Uhr ET abhalten, um die Ergebnisse zu besprechen und ein Update zum Geschäftsgeschehen zu geben. Dial-in-Nummern sind für Inland- und Auslandsgespräche vorgesehen und der Zugangscode 166837 gilt. Ein Live-Webcast ist über die Unternehmensseiten Veranstaltungen/Investor Relations verfügbar und wird später zum Anschauen archiviert. Es wird empfohlen, dass Teilnehmer sich mindestens 15 Minuten vor dem geplanten Start verbinden, um eine rechtzeitige Verbindung sicherzustellen.
شركـة Crinetics للأدوية (ناسداك: CRNX) ستعلن عن نتائج الربع الثالث من عام 2025 في يوم الخميس 6 نوفمبر 2025 بعد إغلاق السوق.
ستعقد الإدارة اتصالًا هاتفيًا وبثًا ويبكاست في تمام الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة لمناقشة النتائج وتقديم تحديث عن الأعمال. ستُقدم أرقام الاتصال للمتصلين من داخل الولايات المتحدة وخارجها وسيطبق رمز الوصول 166837. سيكون هناك بث مباشر عبر صفحات فعاليات/علاقات المستثمرين للشركة وسيتم حفظه لمشاهدته لاحقًا. يُنصح المشاركون بالاتصال قبل 15 دقيقة من البدء المقرر لضمان اتصال في الوقت المحدد.
Crinetics Pharmaceuticals (纳斯达克代码: CRNX) 将在市场收盘后公布 2025 年第三季度 财务业绩，时间为 2025 年 11 月 6 日周四。
管理层将主持一场电话会议和网络广播，时间为 美国东部时间下午 4:30，讨论业绩并提供业务更新。为国内外来电者提供拨号号码，适用 访问码 166837。现场网络广播将通过公司的网站“事件/投资者关系”页面提供，并将被存档以供稍后观看。建议参与者在计划开始时间至少提前 15 分钟连接，以确保及时接入。
- None.
- None.
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
| Conference Call & Webcast | |
| Thursday, November 6 at 4:30 p.m. ET | |
| Domestic: | 1 833-470-1428 |
| International: | 1 646-844-6383 |
| Access Code: | 166837 |
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When will Crinetics Pharmaceuticals (CRNX) report Q3 2025 results?
What time is the CRNX conference call and webcast for Q3 2025?
How can investors join the CRNX Q3 2025 conference call?
Where can I watch the Crinetics (CRNX) Q3 2025 webcast?
Will the CRNX Q3 2025 webcast be available after the call?
Any tips for connecting to the Crinetics Q3 2025 call on November 6?
